Percutaneous mitral valve repair (PMVR) with MitraClip may be a safe and effective alternative for correcting mitral regurgitation (MR) in high-risk patients with acute myocardial infarction, severe MR and considered at risk for conventional surgery, based on findings from the IREMMI trial presented Oct. 17 during TCT 2020.

Rodrigo Estévez-Loureiro, MD, PhD, et al., assessed registry data of all consecutive patients with acute MR following myocardial infarction treated with PMVR at 18 centers in Europe, North America and Israel between January 2016 and March 2020. The primary objectives were acute procedural success and clinical events, including heart failure-related death and readmissions. Outcomes were also compared between patients with and without cardiogenic shock.

"In this very high-risk population, PMVR with MitraClip appears to be a safe and effective alternative for correcting MR and improving patients clinical profile with acceptable rates of death and rehospitalization," said Estévez-Loureiro, et al. Additionally, they note that cardiogenic shock when adequately supported did not seem to influence short and mid-term outcomes and they suggest that "development of cardiogenic shock should not preclude PMVR in this scenario."

Clinical Topics: Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Acute Heart Failure, Interventions and Structural Heart Disease, Mitral Regurgitation

Keywords: TCT20, Transcatheter Cardiovascular Therapeutics, Percutaneous Coronary Intervention, Mitral Valve Insufficiency, Mitral Valve, Shock, Cardiogenic, Myocardial Infarction

< Back to Listings